Precision oncology How can high-quality healthcare remain affordable for all in the face of diagnostic and therapeutic costs?

Medicine is becoming increasingly precise. This is particularly evident in the field of pharmaceuticals and especially in oncology. Driven by the steadily growing understanding of biomedical interrelationships and the resulting increase in precision, we are currently experiencing a paradigm shift from a one-drug-fits-all model towards an individualized biomarker-driven approach. This essentially enables the transition from efficacy to effectiveness. In order to ensure that the promise of high-quality, affordable precision medicine for all remains valid in the future, the step from efficacy in clinical studies to effectiveness in the practice of care is crucial in the next decade. This will be achieved with end-to-end precision from diagnostics to real-world evidence.

Automated summary

Medicine is becoming increasingly precise, particularly in oncology. The shift from a one-drug-fits-all model to an individualized biomarker-driven approach facilitates the transition from efficacy to effectiveness. Ensuring end-to-end precision from diagnostics to real-world evidence is crucial in achieving high-quality, affordable precision medicine for all in the future.